Plate Nº 10 · recorded October 13, 2026
Health & Medicine ResearchReported finding
MIT researchers build microfluidic tool to collect living cancer cells
An MIT microfluidic device uses fluid shear stress to pull living cells from precise tissue spots. Researchers hope it enables earlier ovarian cancer detection. No patient trials yet.
By James Calloway3 min read666 words
In brief
- Five-year ovarian cancer survival exceeds 90% when caught early but falls below 45% in stages 3 and 4.
- MIT and Johns Hopkins researchers described the 3D-printed microfluidic device in the journal Device.
- The Break Through Cancer Foundation funded the work.
- Cells detached by the device grew in culture more readily than those pulled by conventional methods.
- Tests so far used only tissue already removed from patients; no living-patient trials exist.
Early-stage ovarian cancer has a five-year survival rate above 90 percent. The same cancer caught late, in stages 3 or 4? Less than half that.
That gap drives a new handheld device from MIT. The team aims to collect living cells from precise spots in tissue, before the disease spreads.
Professor Kripa Varanasi's group at MIT built the tool with collaborators at MIT and Johns Hopkins University. They described it in a study published in the journal Device.
Why fallopian tubes?
About 20 years ago, researchers found that many high-grade serous ovarian cancers — the most common form — start in the fallopian tubes, not the ovaries.
That shifted prevention. Women at high risk can now have their tubes removed after childbearing, preserving normal hormone production. Detection is harder. Precursor lesions can be microscopic and tough to sample.
The current workflow is destructive. Tissue gets preserved in chemicals, sliced, and examined by a pathologist under a microscope. Cells die. They cannot be grown.
What does the device actually do?
The system is a 3D-printed microfluidic chip that vacuum-seals against tissue. A second syringe pushes liquid through a small channel. That flow creates shear stress parallel to the tissue surface — gentle pulling that shears living cells loose while leaving the surrounding tissue mostly intact.
"We wanted to collect living cells from specific regions of the fallopian tube while leaving the surrounding tissue intact," Varanasi said. "Once we have these living cells, there are many things we can do with them."
The team tested the device on freshly removed human fallopian tubes, often shipped same-day from Johns Hopkins.
"The samples could come at any time," said co-first author Bert Vandereydt, an MIT postdoc. "Sometimes, we'd get an email saying 'There are two fallopian tubes coming tomorrow.'"
The finding: cells collected this way stayed alive and grew in culture far more readily than cells pulled by conventional methods.
What changes for patients?
Short answer: not much, yet.
The work is preliminary. The device has only been tested on tissue that surgeons already removed. No patient trials exist. Diagnostic accuracy is unknown.
Regulatory approval for in-body use will take years.
"It's agnostic to the disease," Vandereydt said. Prostate cancer cells detach at about 1 pascal of shear stress. Bone cancer cells barely budge at 5 pascals. Tune the pressure, collect different cells.
That range matters more in the lab than the clinic right now.
The team
Authors listed on the paper:
- Domitille Avalle (SM '25), co-first author
- Bert Vandereydt (PhD '26), co-first author
- Sean Parks ('20, SM '24), co-first author
- Huaiyao Peng, MIT PhD candidate
- Rebecca Stone, Johns Hopkins gynecologic oncologist
- Angela Belcher, MIT professor of biological engineering
The Break Through Cancer Foundation funded the work. Varanasi credited the foundation for pulling together ovarian, pancreatic, brain, and leukemia researchers under one roof.
What's still unproven?
No tests on living patients. No data on how often the device finds early lesions — or misses them. No evidence yet that the cells it collects will change treatment decisions.
Rebecca Stone of Johns Hopkins kept her reaction measured.
"What is exciting about this technology is the ability to collect living cells from a specific area while preserving the tissue for pathology," she said. "In the future, one could imagine integrating it into routine histopathology workflows."
That "could" is doing real work.
Why it still matters
Even if the device never reaches a living patient, it could change how researchers study cancer at its earliest stages. Living cells behave differently than preserved ones. They form organoids. They respond to drugs. They reveal mechanisms that dead tissue cannot.
If larger studies hold up, pathologists gain a tool that keeps tissue intact while pulling living cells out for follow-up work.
Real shift. Not a small one.
Question now is how fast it moves from lab curiosity to clinical practice. The MIT team has the engineering. Trials, regulatory pathway, and funding still need solving.
via seer.cancer.gov (Original)
More from James Calloway
Show full bio
Staff writer covering regulation, policy and their impact on general science news at SciBeat.
224 articles
Nearby plates
- Inflammation Can Wake Up 'Sleeping' Cancer Cells Hidden in Bone
- Magnetic Nanoparticles Target Ectopic Pregnancy Tissue in Mice
- MIT team builds method that lets living cells mail out their own RNA
- Virtual Patients Could Catch Device Risks Real Trials Miss
- Nanoparticles flag and destroy hidden glioblastoma cells in mice